Switching from Infliximab Originator to SB2 Biosimilar in Inflammatory Bowel Diseases: A Multicentric Prospective Real-Life Study.
Davide MassimiBrigida BarberioLorenzo BertaniFrancesco CostaAntonio FerronatoSonia FacchinRomilda CardinLinda CingolaniCesare CasadeiRenata D'IncàFabiana ZingoneEdoardo Vincenzo SavarinoPublished in: Therapeutic advances in gastroenterology (2021)
Overall, our data show that most of the patients switching from Infliximab originator to SB2 maintain the clinical and biochemical remission for at least 1 year. Further data are necessary to understand the clinical implications of these findings in the long term.